Skip to main content

​
Summary

You must prepare and submit appropriate premarket applications to FDA to obtain marketing authorization for your medical device in the United States through 510(k) clearance, PMA approval, or De Novo classification pathways. This comprehensive submission process demonstrates substantial equivalence, safety and effectiveness, or establishes new device classifications while providing FDA with evidence necessary for confident marketing authorization decisions.

​
Regulatory Context

Under 21 CFR Part 807 (Premarket Notification) and 21 CFR Part 814 (PMA), you must comply with:
  • 510(k) clearance per Section 807.81 for most Class II devices demonstrating substantial equivalence
  • PMA approval per Part 814 for Class III devices requiring safety and effectiveness evidence
  • De Novo classification per Section 807.85 for novel devices without appropriate predicates
  • eSTAR electronic submission per Section 807.87 using FDA electronic submission systems
  • User fee payment per MDUFA requirements accompanying submission
Special attention required for:
  • Software validation per FDA software guidance requiring comprehensive lifecycle documentation
  • Cybersecurity considerations per FDA premarket cybersecurity guidance for networked devices
  • Clinical data requirements varying by device classification and intended use
  • Predicate device comparison ensuring appropriate substantial equivalence demonstration

​
Overview

FDA Submission represents the culminating regulatory activity that transforms completed device development into market-ready medical devices through comprehensive demonstration of safety, effectiveness, and regulatory compliance to FDA reviewers. This critical submission process requires systematic compilation of technical evidence, clinical data, and regulatory documentation that enables FDA to make confident marketing authorization decisions while establishing the regulatory foundation for successful US commercial launch. Submission Pathway Determination establishes the appropriate regulatory route for your device based on classification, risk profile, and predicate device availability while optimizing regulatory efficiency and approval probability. Pathway determination requires comprehensive analysis of device characteristics and intended use to confirm appropriate classification, systematic evaluation of available predicate devices to assess substantial equivalence potential, and assessment of clinical data requirements that vary significantly between 510(k), PMA, and De Novo pathways. Effective pathway selection balances regulatory requirements with development resources while ensuring optimal approval probability and time to market. 510(k) Submission Preparation demonstrates substantial equivalence to legally marketed predicate devices through systematic comparison of intended use, technological characteristics, and performance data. 510(k) preparation requires identification and analysis of appropriate predicate devices that share similar intended use and technological characteristics, comprehensive comparison across safety and effectiveness parameters including bench testing, software validation, and clinical evidence where required. Submission development includes preparation of clear and concise equivalence arguments, compilation of supporting technical data and testing evidence, and presentation of information in formats that facilitate efficient FDA review and approval. Clinical Data Strategy and Integration provides appropriate clinical evidence to support safety and effectiveness claims while addressing FDA reviewer expectations and regulatory requirements. Clinical strategy requires assessment of clinical data requirements based on device classification and novelty, integration of clinical evaluation findings with FDA submission requirements, and presentation of clinical evidence in formats that support regulatory decision-making. Clinical integration ensures that clinical data directly addresses intended use claims while providing adequate evidence for FDA reviewer confidence in device safety and effectiveness. Technical Documentation Compilation organizes comprehensive technical evidence including design controls, risk management, verification and validation, and manufacturing information into coherent submission packages. Documentation compilation requires systematic organization of Design History File contents into FDA submission format, integration of risk management findings with safety and effectiveness claims, and presentation of verification and validation evidence that demonstrates device performance and reliability. Technical compilation ensures that all required information is complete, accurate, and presented in logical order that facilitates FDA review efficiency. Electronic Submission Preparation and Management ensures proper formatting, organization, and submission of electronic files through FDA eSTAR system while maintaining data integrity and submission quality. Electronic preparation requires understanding of FDA electronic submission requirements and formatting specifications, organization of submission files in eCTD format with appropriate folder structure and file naming, and implementation of quality control procedures that ensure submission completeness and accuracy. Electronic management includes coordination of submission timing with regulatory strategy while ensuring proper user fee payment and acknowledgment procedures. Regulatory Communication and Interaction facilitates effective communication with FDA throughout the submission review process while addressing reviewer questions and requests for additional information efficiently. Communication management requires preparation for potential FDA questions through comprehensive submission content and supporting documentation, establishment of procedures for responding to FDA requests for additional information within specified timeframes, and coordination with FDA review team through appropriate communication channels. Effective communication ensures efficient review process while demonstrating responsive regulatory engagement. Software Documentation and Validation Evidence addresses unique FDA requirements for software medical devices including software lifecycle documentation, cybersecurity considerations, and algorithm validation evidence. Software documentation requires comprehensive software development lifecycle evidence per FDA software guidance, detailed cybersecurity risk assessment and control documentation for networked devices, and extensive testing evidence that demonstrates software safety and effectiveness under normal and fault conditions. Software submissions must address regulatory expectations for software quality assurance, change control, and post-market software maintenance procedures. Quality System and Manufacturing Documentation demonstrates manufacturing capability and quality control systems that ensure consistent device production and quality throughout commercial manufacturing. Manufacturing documentation requires evidence of design transfer from development to production, comprehensive manufacturing procedures and quality control systems, and validation evidence that demonstrates manufacturing process capability and control. Quality system documentation must demonstrate compliance with FDA Quality System Regulation while providing confidence in ongoing manufacturing quality and consistency. Post-Approval Considerations and Planning prepares for post-market obligations and ongoing regulatory compliance activities that begin following FDA clearance or approval. Post-approval planning requires understanding of labeling requirements and marketing claim limitations established by FDA clearance or approval, implementation of post-market surveillance systems that monitor device performance and safety, and establishment of procedures for managing device changes and reporting requirements. Effective planning ensures smooth transition from approval to commercial launch while maintaining ongoing regulatory compliance and stakeholder confidence. Multi-Jurisdictional Coordination optimizes submission strategy for devices seeking approval in multiple markets by coordinating FDA submissions with EU MDR and other international regulatory requirements. International coordination requires alignment of clinical data and technical documentation across multiple jurisdictions, optimization of submission timing to support global launch strategies, and coordination of regulatory interactions to avoid conflicting requirements or inefficiencies. Effective coordination enables efficient global regulatory approval while minimizing redundant efforts and maximizing regulatory efficiency. Your FDA Submission activities must demonstrate comprehensive regulatory excellence while providing FDA reviewers with complete, accurate, and compelling evidence for confident marketing authorization decisions. Well-executed submission processes provide FDA with systematic evidence of device safety and effectiveness, demonstrate professional regulatory capability and compliance commitment, and establish the regulatory foundation for successful long-term US market presence through demonstrated adherence to rigorous FDA standards and professional regulatory management.